SCHEMBL24655828

SCHEMBL24655828

CNC(=O)c1ncc(N)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.39
HDAC6 Q9UBN7 4/20 0.36
HDAC1 Q13547 3/20 0.36
BAZ2B Q9UIF8 1/20 0.36
PTPN11 Q06124 1/20 0.36
SCN9A Q15858 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
CNR1 P21554 1/20 0.34
PTK2 Q05397 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
PARP1 P09874 1/20 0.34
MAP4K1 Q92918 1/20 0.34
PIP5K1C O60331 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12179242 0.80 CNR1 (0.42) P2RX7HDAC6HDAC1BAZ2BHDAC2
SCHEMBL14903866 0.78 PTK2 (0.40) BAZ2BSCN9ASCN2ASCN3ASCN10A
SCHEMBL658490 0.78 CREBBP (0.41) P2RX7HDAC6HDAC1BAZ2BHDAC2
SCHEMBL24656054 0.77 SUV39H1 (0.37) P2RX7HDAC6HDAC1JAK2
SCHEMBL16472309 0.75 NPC1 (0.41) P2RX7HDAC6BAZ2BSCN2AHDAC2
SCHEMBL25738793 0.75 PLK1 (0.50) P2RX7BAZ2BPARP1PLK1
SCHEMBL23771951 0.75 POLB (0.42) HDAC1BAZ2BJAK2JAK1TYK2
SCHEMBL28940975 0.75 MEN1 (0.37) P2RX7BAZ2BPARP1MAP4K1PLK1
SCHEMBL2363536 0.75 P2RX7 (0.60) P2RX7HDAC6BAZ2BHDAC2HDAC8
SCHEMBL9950882 0.74 TSHR (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334298-B1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-20250250259-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2025-08-07 US disclosed
US-12312341-B2 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2025-05-27 US disclosed
US-20240400543-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-12-05 US disclosed
US-20240300939-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. 2024-09-12 US disclosed
US-12084434-B2 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2024-09-10 US disclosed
US-20240158376-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-05-16 US disclosed
CN-117813293-A Urea derivatives useful for the treatment of cancer 蝎子疗法股份有限公司 2024-04-02 CN disclosed
EP-4334298-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER Scorpion Therapeutics, Inc. (US) 2024-03-13 EP disclosed
US-20240076289-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-03-07 US disclosed
US-11897871-B1 Methods for treating cancer SCORPION THERAPEUTICS, INC. (US) 2024-02-13 US disclosed
WO-2022265993-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
WO-2022265993-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300939-A1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER PIK3CA, PIK3CG, PIK3CD P2RX7 1721/4885HDAC6 809/4885HDAC1 1013/4885
US-20240158376-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885
US-11897871-B1 Methods for treating cancer PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885
US-12312341-B2 Methods for treating cancer PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885
US-20240076289-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885
US-20250250259-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885
US-20240400543-A1 METHODS FOR TREATING CANCER PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885
US-12084434-B2 Methods for treating cancer PIK3CA, PTEN, BRCA1 P2RX7 1974/4885HDAC6 146/4885HDAC1 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.